Literature DB >> 27063590

Survival Outcomes of Mucosal Melanoma in the Head and Neck: Case Series and Review of Current Treatment Guidelines.

Omar Breik1, Felix Sim2, Tim Wong3, Alf Nastri4, Tim A Iseli5, David Wiesenfeld6.   

Abstract

PURPOSE: Malignant mucosal melanoma of the head and neck (MMHN) is an aggressive and rare neoplasm with poor long-term outcomes. The aim of this study is to evaluate the outcomes of patients treated by a single-institution head and neck multidisciplinary team.
MATERIALS AND METHODS: In this retrospective case series, all MMHN cases treated at the Royal Melbourne Hospital from 1990-2015 were retrospectively reviewed. Patient demographic characteristics (eg, age), treatment offered, pathology, and outcomes were collected, tabulated, and correlated with outcomes. Survival outcomes were calculated by the Kaplan-Meier method. Comparison was made between oral and sinonasal melanomas.
RESULTS: A total of 16 cases were identified. Two were excluded because of inaccessible data. Of the 14 remaining cases, 8 were sinonasal melanomas and 6 were oral cavity melanomas. Sinonasal tumor patients presented with epistaxis or visual impairment. Oral melanoma patients presented with pigmented lesions or ulceration. Follow-up ranged from 4 months to 11 years. In 2 patients, locoregional recurrences developed that were successfully re-excised. Six patients died of distant metastases despite clear surgical margins. Two patients with sinonasal melanomas died of extensive local disease with intracranial invasion. One patient died 4 years after diagnosis without disease. There were no failures in the neck. The 2- and 5-year overall survival rates were 63.3% and 31.7%, respectively, by the Kaplan-Meier method. The difference in survival between oral and sinonasal melanomas was not statistically significant.
CONCLUSIONS: Despite clear surgical margins, MMHN has a poor prognosis and most deaths are due to distant metastases. Systemic therapies such as those used in cutaneous melanoma treatment might be used in the future for MMHN.
Copyright © 2016 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27063590     DOI: 10.1016/j.joms.2016.03.008

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  7 in total

1.  Oral malignant melanoma of alveolar ridge.

Authors:  Madhusudan Astekar; Rajkumar R Choubey; Bhari Sharanesha Manjunatha; Santosh Gupta
Journal:  BMJ Case Rep       Date:  2019-05-31

2.  Altered expression pattern of circular RNAs in metastatic oral mucosal melanoma.

Authors:  Houyu Ju; Liming Zhang; Lu Mao; Shuli Liu; Weiya Xia; Jingzhou Hu; Min Ruan; Guoxin Ren
Journal:  Am J Cancer Res       Date:  2018-09-01       Impact factor: 6.166

3.  Amelanotic Malignant Mucosal Melanoma of the Nasal Cavity: Case Report and Literature Review.

Authors:  Ilias Tahiri; Othman El Houari; Amal Hajjij; Mohammed Zalagh; Fouad Benariba
Journal:  Cureus       Date:  2022-02-21

Review 4.  Distant metastasis from oral cavity-correlation between histopathology results and primary site.

Authors:  Yuka Uchiyama; Tadashi Sasai; Atsutoshi Nakatani; Hiroaki Shimamoto; Tomomi Tsujimoto; Sven Kreiborg; Shumei Murakami
Journal:  Oral Radiol       Date:  2020-05-28       Impact factor: 1.852

Review 5.  A Review of the Aetiopathogenesis and Clinical and Histopathological Features of Oral Mucosal Melanoma.

Authors:  Liviu Feller; Razia A G Khammissa; Johan Lemmer
Journal:  ScientificWorldJournal       Date:  2017-05-30

6.  Radiotherapy alone as a method of treatment for sinonasal mucosal melanoma: A report based on six cases and a review of current opinion.

Authors:  Beata Sas-Korczynska; Marian Reinfuss; Jerzy W Mitus; Elzbieta Pluta; Anna Patla; Tomasz Walasek
Journal:  Rep Pract Oncol Radiother       Date:  2018-08-17

7.  Sinonasal mucosal melanoma: a 10-year experience of 36 cases in China.

Authors:  Tan Wang; Yue Huang; Jingrong Lu; Mingliang Xiang
Journal:  Ann Transl Med       Date:  2020-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.